Mark Lomaga
Probity Medical Research(CA)
Publications by Year
Research Areas
Psoriasis: Treatment and Pathogenesis, Dermatology and Skin Diseases, Asthma and respiratory diseases, Autoimmune Bullous Skin Diseases, Pharmaceutical studies and practices
Most-Cited Works
- → TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling(1999)1,267 cited
- → Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study(2017)185 cited
- → A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial(2019)168 cited
- → Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis(2022)107 cited
- → Tumor Necrosis Factor Receptor-Associated Factor 6 (TRAF6) Deficiency Results in Exencephaly and Is Required for Apoptosis within the Developing CNS(2000)87 cited
- → Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children(2024)48 cited
- → Results of Patch Testing in Patients Diagnosed with Oral Lichen Planus(2009)18 cited
- → Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial(2019)14 cited
- → An Analysis of Patient-reported Outcomes in IXORA-S: Comparing Ixekizumab and Ustekinumab over 52 Weeks in Moderate-to-severe Psoriasis(2020)10 cited
- Priapism as a possible acute side effect of radical radiotherapy for prostate cancer.(2004)